Impact BioMedical's merger terms revised, sending shares soaring over 115%
Impact BioMedical (IBO) has revised its merger terms with Dr Ashleys Limited, pushing the completion deadline to July 1, 2026. The announcement triggered a sharp rise in IBO's share price, with pre-market trading surging over 115% after an SEC filing revealed key changes to the deal.
Under the updated agreement, Impact BioMedical will receive 169.56 million shares of the combined company, known as PubCo. This stake grants it 94.20% ownership of the merged entity. Parent firm DSS, Inc. retains an 88.87% interest in IBO on a fully diluted basis and holds rights to an additional 53,000 shares for indemnification.
The merger's timeline has shifted significantly. Originally announced on June 21, 2025, the deal now faces an extended closing date of July 1, 2026. Meanwhile, the stock of Kyntra Bio—the post-merger name for Impact BioMedical—was trading at 6.00€ as of March 4, 2026. Over the past year, its performance showed a dramatic swing: a 1,596.43% gain, though the past 12 months saw a 26.92% decline.
IBO's own shares closed at $0.41 on Wednesday, well below their 52-week high of $6.17. The stock had fluctuated between $0.36 and $6.17 over the past year before the latest merger update.
The revised merger terms give Impact BioMedical near-total control of the new company. The extended deadline provides more time to finalise the deal, while the share price reaction reflects investor interest in the changes. Kyntra Bio's long-term performance remains volatile, with sharp gains followed by recent losses.
